Key Takeaways Sanofi (SNY) reported second-quarter 2025 adjusted earnings of 90 cents per American depositary share, which missed the Zacks Consensus Estimate of 96 cents per share. Earnings of €1.59 per share rose 1.9% on a reported basis and 8.3% on a constant currency rate ("CER") basis. Net sales rose 6% on a reported basis to $11.33 billion (€10.0 billion). Sales rose 10.1% on a CER basis. Sales missed the Zacks Consensus Estimate of $11.53 billion. Sales rose 17.3% at CER in the United States, 4.4% in ...

7 月 31 日，赛诺菲官方微信发布二季报财报。数据显示，第二季度，公司实现营收额为100亿欧元 （约 114亿美元），增长 10.1%；今年上半年，公司实现总营收额为 198.89 亿欧元（约 226 亿美元）， 增长 9.9%。（汇率1 欧元=1.14 美元）。研发投入为37.17欧元（约42亿美元），占总营收的18.7%。 从区域收益看，今年上半年：赛诺菲在美国市场的收入最多，为 95.35 亿欧元（约108.8亿美元）， 增长 16.4%；欧洲市场销售额为 41.44 亿欧元（约47.2亿美元），增长 1.8%；中国市场收入为 13.88 亿 欧元（约合15.8亿美元），增长 0.1%。 此前，赛诺菲此前押注了罕见病领域，产品布局方面，公司推出Altuviiio（A 型血友病药物）、晚 发性庞贝病替代疗法Nexviazyme（艾夫糖苷酶α）、治疗酸性鞘磷脂酶缺乏症的Xenpozyme等12款产品 矩阵。其中，血友病药物Altuviiio在上市两年内迅速渗透市场，今年上半年销售额已经达到5.42亿欧 元。在血友病领域，赛诺菲的另一款重要产品，成为该领域首款RNAi疗法，上市三个月收入100万美 元。 赛 ...

Core Viewpoint - Sanofi's stock has been underperforming, trading below its 50-day and 200-day moving averages, raising concerns among investors about its future direction [1][2][8]. Group 1: Dupixent and Vaccine Segment - Dupixent, developed in partnership with Regeneron, is a significant revenue driver for Sanofi, approved for multiple inflammatory diseases and expected to generate around €22 billion in sales by 2030 [3][4]. - Sanofi's vaccine segment has shown strong performance, with annual sales exceeding €5 billion and a 13.5% sales growth at constant exchange rates (CER) in 2024, driven by the successful rollout of Beyfortus [5][12]. Group 2: New Products and Pipeline - Sanofi's new products, including Altuviiio and Beyfortus, are contributing to revenue growth, with Beyfortus achieving blockbuster status in its first year [6][7]. - The company has a robust pipeline with 12 potential blockbuster assets in phase III development, including amlitelimab and tolebrutinib [9][10]. Group 3: Financial Performance and Valuation - Sanofi's stock has increased by 3.1% year-to-date, outperforming the industry and S&P 500, with a price/earnings ratio of 10.15, lower than the industry average of 14.81 [14][17]. - Earnings estimates for 2025 and 2026 have risen, reflecting positive momentum from new product launches and pipeline developments [20][24]. Group 4: Challenges and Strategic Moves - The launch of generic versions of Aubagio has negatively impacted its sales, and the influenza vaccine segment is facing competitive pressures [11][12][22]. - Sanofi is actively pursuing mergers and acquisitions to enhance its pipeline, with recent proposed acquisitions of Blueprint Medicines and Vigil Neuroscience [23].

Sanofi (SNY) reported first-quarter 2025 adjusted earnings of 94 cents per American depositary share, which beat the Zacks Consensus Estimate of 90 cents per share. Earnings of €1.79 per share rose 17.0% on a reported basis and 15.7% on a constant currency rate ("CER") basis. Net sales rose 10.8% on a reported basis to $10.42 billion (€9.9 billion). Exchange rate movements benefited sales by 1.1% in the quarter. Sales rose 9.7% on a CER basis. Sales, however, missed the Zacks Consensus Estimate of $10.63 bi ...

Group 1 - Sanofi has signed an agreement to acquire Dren Bio's investigational bispecific antibody DR-0201, which targets CD20 and is designed for deep B-cell depletion [1][2] - The acquisition includes an upfront payment of $600 million and potential milestone payments of up to $1.3 billion, with the deal expected to close in Q2 2025 [2] - Dren Bio has previously secured multi-billion dollar partnerships with Novartis and Pfizer for its bispecific antibody technology [3] Group 2 - Sanofi aims to enhance its immunology pipeline and position itself as a leading immunology company, with 12 potential blockbuster assets in phase III development [6] - The success of these candidates will reduce reliance on Dupixent, which generated over €13 billion in sales in 2024, accounting for about one-third of Sanofi's total revenues [7] - Sanofi is also focusing on new product launches, expecting three new products launched in 2023 to collectively achieve at least €5 billion in peak sales [8] Group 3 - Year-to-date, Sanofi's stock has increased nearly 22%, outperforming the industry growth of 7% [4]